Dalbavancin

Marguerite L. Monogue; David P. Nicolau

doi:10.1201/9781315152110

Dalbavancin

Marguerite L. Monogue, David P. Nicolau

Research output: Chapter in Book/Report/Conference proceeding › Chapter

1 Scopus citations

Abstract

Dalbavancin (Dalvance, Xydalba) is a semisynthetic lipoglycopeptide approved in 2014 by the US Food and Drug Administration (FDA) and in 2015 by the European Medicines Agency for acute bacterial skin and skin structure infections (ABSSSIs) caused by susceptible Grampositive isolates in adults. Although originally approved for a twodose regimen, the compound has an extended halflife (t1/2) that enables singledose therapy for ABSSSIs (Dunne et al., 2016a; Dunne et al., 2016b). Dalbavancin has potent in vitro activity against most Grampositive organisms with lower minimum inhibitory concentration (MIC) values than vancomycin and other investigational lipoglycopeptides (i.e. oritavancin, telavancin). It is also active against drugresistant pathogens of concern such as methicillinresistant Staphylococcus aureus (MRSA) and vancomycinresistant enterococci (VRE), except for strains exhibiting vanA resistance.

Original language	English (US)
Title of host publication	Kucers the Use of Antibiotics
Subtitle of host publication	A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition
Publisher	CRC Press
Pages	917-929
Number of pages	13
ISBN (Electronic)	9781498747967
ISBN (Print)	9781498747950
DOIs	https://doi.org/10.1201/9781315152110
State	Published - Jan 1 2017
Externally published	Yes

ASJC Scopus subject areas

General Pharmacology, Toxicology and Pharmaceutics
General Medicine

Access to Document

10.1201/9781315152110

Cite this

@inbook{7e99e10e6f884b59b6860f6d50839207,

title = "Dalbavancin",

abstract = "Dalbavancin (Dalvance, Xydalba) is a semisynthetic lipoglycopeptide approved in 2014 by the US Food and Drug Administration (FDA) and in 2015 by the European Medicines Agency for acute bacterial skin and skin structure infections (ABSSSIs) caused by susceptible Grampositive isolates in adults. Although originally approved for a twodose regimen, the compound has an extended halflife (t1/2) that enables singledose therapy for ABSSSIs (Dunne et al., 2016a; Dunne et al., 2016b). Dalbavancin has potent in vitro activity against most Grampositive organisms with lower minimum inhibitory concentration (MIC) values than vancomycin and other investigational lipoglycopeptides (i.e. oritavancin, telavancin). It is also active against drugresistant pathogens of concern such as methicillinresistant Staphylococcus aureus (MRSA) and vancomycinresistant enterococci (VRE), except for strains exhibiting vanA resistance.",

author = "Monogue, {Marguerite L.} and Nicolau, {David P.}",

note = "Publisher Copyright: {\textcopyright} 2018 by Taylor & Francis Group, LLC.",

year = "2017",

month = jan,

day = "1",

doi = "10.1201/9781315152110",

language = "English (US)",

isbn = "9781498747950",

pages = "917--929",

booktitle = "Kucers the Use of Antibiotics",

publisher = "CRC Press",

}

TY - CHAP

T1 - Dalbavancin

AU - Monogue, Marguerite L.

AU - Nicolau, David P.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Dalbavancin (Dalvance, Xydalba) is a semisynthetic lipoglycopeptide approved in 2014 by the US Food and Drug Administration (FDA) and in 2015 by the European Medicines Agency for acute bacterial skin and skin structure infections (ABSSSIs) caused by susceptible Grampositive isolates in adults. Although originally approved for a twodose regimen, the compound has an extended halflife (t1/2) that enables singledose therapy for ABSSSIs (Dunne et al., 2016a; Dunne et al., 2016b). Dalbavancin has potent in vitro activity against most Grampositive organisms with lower minimum inhibitory concentration (MIC) values than vancomycin and other investigational lipoglycopeptides (i.e. oritavancin, telavancin). It is also active against drugresistant pathogens of concern such as methicillinresistant Staphylococcus aureus (MRSA) and vancomycinresistant enterococci (VRE), except for strains exhibiting vanA resistance.

AB - Dalbavancin (Dalvance, Xydalba) is a semisynthetic lipoglycopeptide approved in 2014 by the US Food and Drug Administration (FDA) and in 2015 by the European Medicines Agency for acute bacterial skin and skin structure infections (ABSSSIs) caused by susceptible Grampositive isolates in adults. Although originally approved for a twodose regimen, the compound has an extended halflife (t1/2) that enables singledose therapy for ABSSSIs (Dunne et al., 2016a; Dunne et al., 2016b). Dalbavancin has potent in vitro activity against most Grampositive organisms with lower minimum inhibitory concentration (MIC) values than vancomycin and other investigational lipoglycopeptides (i.e. oritavancin, telavancin). It is also active against drugresistant pathogens of concern such as methicillinresistant Staphylococcus aureus (MRSA) and vancomycinresistant enterococci (VRE), except for strains exhibiting vanA resistance.

UR - http://www.scopus.com/inward/record.url?scp=85056687799&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056687799&partnerID=8YFLogxK

U2 - 10.1201/9781315152110

DO - 10.1201/9781315152110

M3 - Chapter

AN - SCOPUS:85056687799

SN - 9781498747950

SP - 917

EP - 929

BT - Kucers the Use of Antibiotics

PB - CRC Press

ER -

Dalbavancin

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this